Your browser doesn't support javascript.
loading
Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
Rao, V Koneti; Webster, Sharon; Dalm, Virgil A S H; Sedivá, Anna; van Hagen, P Martin; Holland, Steven; Rosenzweig, Sergio D; Christ, Andreas D; Sloth, Birgitte; Cabanski, Maciej; Joshi, Aniket D; de Buck, Stefan; Doucet, Julie; Guerini, Danilo; Kalis, Christoph; Pylvaenaeinen, Ilona; Soldermann, Nicolas; Kashyap, Anuj; Uzel, Gulbu; Lenardo, Michael J; Patel, Dhavalkumar D; Lucas, Carrie L; Burkhart, Christoph.
Afiliación
  • Rao VK; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD.
  • Webster S; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD.
  • Dalm VASH; Department of Internal Medicine and.
  • Sedivá A; Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.
  • van Hagen PM; Department of Immunology, Motol University Hospital, Prague, Czech Republic.
  • Holland S; Department of Internal Medicine and.
  • Rosenzweig SD; Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.
  • Christ AD; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD.
  • Sloth B; NIH Clinical Center, Bethesda, MD.
  • Cabanski M; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • Joshi AD; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • de Buck S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • Doucet J; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • Guerini D; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA.
  • Kalis C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • Pylvaenaeinen I; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • Soldermann N; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • Kashyap A; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • Uzel G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • Lenardo MJ; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and.
  • Patel DD; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD.
  • Lucas CL; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD.
  • Burkhart C; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD.
Blood ; 130(21): 2307-2316, 2017 11 23.
Article en En | MEDLINE | ID: mdl-28972011
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Pirimidinas / Inhibidores de Proteínas Quinasas / Fosfatidilinositol 3-Quinasa Clase I / Terapia Molecular Dirigida / Síndromes de Inmunodeficiencia Tipo de estudio: Risk_factors_studies Idioma: En Revista: Blood Año: 2017 Tipo del documento: Article País de afiliación: Moldova
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Pirimidinas / Inhibidores de Proteínas Quinasas / Fosfatidilinositol 3-Quinasa Clase I / Terapia Molecular Dirigida / Síndromes de Inmunodeficiencia Tipo de estudio: Risk_factors_studies Idioma: En Revista: Blood Año: 2017 Tipo del documento: Article País de afiliación: Moldova